For the quarter ending 2025-09-30, TOVX made $4,519K in revenue. -$4,361K in net income. Net profit margin of -96.50%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,889 | 11,179 | ||
| Research and development | 2,551 | 1,953 | ||
| Total operating costs and expenses | 4,440 | 13,132 | ||
| Loss from operations | -4,440 | -13,132 | ||
| Foreign currency exchange (loss) gain | 14 | 20 | ||
| Interest income, net | 65 | 54 | ||
| Total other income | 79 | 74 | ||
| Net loss | -4,361 | -13,058 | ||
| Net loss attributable to common stockholders | -4,361 | -13,058 | ||
| Earnings per share, basic | -0.45 | -1.93 | ||
| Earnings per share, diluted | -0.45 | -1.93 | ||
| Weighted average number of shares outstanding, basic | 9,676,521 | 6,752,953 | ||
| Weighted average number of shares outstanding, diluted | 9,676,521 | 6,752,953 | ||
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)